Stockscreener 앱 받기
39.78
0.33%
0.13
시간 외 거래:
39.78
전일 마감가:
$39.65
열려 있는:
$38.96
하루 거래량:
2.64M
Relative Volume:
0.94
시가총액:
$7.33B
수익:
$217.77M
순이익/손실:
$-438.86M
주가수익비율:
-16.51
EPS:
-2.41
순현금흐름:
$-456.33M
1주 성능:
+3.00%
1개월 성능:
+19.60%
6개월 성능:
+44.71%
1년 성능:
+37.17%
1일 변동 폭
$38.57
$39.81
1주일 범위
$38.57
$40.40
52주 변동 폭
$21.62
$40.40
Bridgebio Pharma Inc Stock (BBIO) Company Profile
명칭
Bridgebio Pharma Inc
전화
(650) 391-9740
주소
3160 PORTER DR., PALO ALTO, CA
BBIO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BBIO
Bridgebio Pharma Inc
|
39.78 | 7.33B | 217.77M | -438.86M | -456.33M | -2.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.45 | 115.69B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
529.24 | 53.25B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
307.99 | 39.22B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.89 | 35.78B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
269.63 | 27.68B | 3.81B | -644.79M | -669.77M | -6.24 |
Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-31 | 개시 | Redburn Atlantic | Buy |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-10-03 | 개시 | Oppenheimer | Perform |
| 2024-09-04 | 개시 | Piper Sandler | Overweight |
| 2024-03-21 | 재개 | Raymond James | Outperform |
| 2024-01-31 | 개시 | BMO Capital Markets | Market Perform |
| 2023-12-08 | 개시 | Wells Fargo | Overweight |
| 2023-11-07 | 개시 | Citigroup | Buy |
| 2023-10-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-07-18 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-04-19 | 개시 | Evercore ISI | Outperform |
| 2023-02-06 | 개시 | Cowen | Outperform |
| 2021-12-27 | 재확인 | Mizuho | Buy |
| 2021-12-27 | 재확인 | SVB Leerink | Outperform |
| 2021-09-10 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2021-05-21 | 개시 | UBS | Buy |
| 2021-03-22 | 재확인 | Goldman | Buy |
| 2021-02-22 | 재개 | JP Morgan | Overweight |
| 2021-02-09 | 재개 | Goldman | Buy |
| 2021-01-11 | 재확인 | H.C. Wainwright | Buy |
| 2020-12-10 | 재확인 | H.C. Wainwright | Buy |
| 2020-06-25 | 개시 | BofA/Merrill | Neutral |
| 2020-05-19 | 개시 | BTIG Research | Buy |
| 2020-04-13 | 개시 | H.C. Wainwright | Buy |
| 2020-02-19 | 개시 | Mizuho | Buy |
| 2019-07-26 | 개시 | Raymond James | Outperform |
| 2019-07-22 | 개시 | BMO Capital Markets | Outperform |
| 2019-07-22 | 개시 | Goldman | Buy |
| 2019-07-22 | 개시 | JP Morgan | Overweight |
| 2019-07-22 | 개시 | Jefferies | Buy |
| 2019-07-22 | 개시 | Piper Jaffray | Overweight |
| 2019-07-22 | 개시 | SVB Leerink | Outperform |
모두보기
Bridgebio Pharma Inc 주식(BBIO)의 최신 뉴스
BridgeBio Pharma, Inc. (BBIO) Price Target Raised to $56 from $53 at H.C. Wainwright - MSN
BridgeBio Pharma’s SWOT analysis: stock poised for growth amid challenges - Investing.com
When the Price of (BBIO) Talks, People Listen - news.stocktradersdaily.com
13 Biotech Stocks with Huge Upside Potential - Insider Monkey
Day 8 of Gains Streak for BridgeBio Pharma Stock with 21% Return (vs. 42% YTD) [6/9/2025] - Trefis
BridgeBio stock holds Buy rating, price target at $56H.C. Wainwright - Investing.com Canada
Transcript : BridgeBio Pharma, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 08 - marketscreener.com
BridgeBio Pharma (BBIO) Sees Price Target Increase by HC Wainwri - GuruFocus
BridgeBio Pharma (BBIO) Sees Price Target Increase by HC Wainwright & Co. | BBIO Stock News - GuruFocus
BridgeBio (BBIO) Price Target Raised to $56 by H.C. Wainwright | BBIO Stock News - GuruFocus
Breakthrough Growth in Transthyretin Amyloid Cardiomyopathy - openPR.com
Why BridgeBio Pharma, Inc. (BBIO) Surged on Wednesday - MSN
BridgeBio Pharma stock hits 52-week high at $39.58 By Investing.com - Investing.com South Africa
BridgeBio Pharma stock hits 52-week high at $39.58 - Investing.com Australia
BMO Maintains Hold on BridgeBio (BBIO) Amid Intensifying Competition - MSN
Piper Sandler maintains overweight rating on BridgeBio Pharma stock - Investing.com
Piper Sandler maintains overweight rating on BridgeBio Pharma stock By Investing.com - Investing.com UK
BridgeBio Pharma doses first asymptomatic subject in study of ATTR prevention drug - MSN
BridgeBio price target raised to $42 from $37 at BMO Capital - Yahoo Finance
BMO Capital raises BridgeBio Pharma stock price target to $42 By Investing.com - Investing.com UK
BridgeBio (BBIO) Target Price Raised by BMO Capital | BBIO Stock News - GuruFocus
Exploring High Growth Tech Stocks In The US Market - simplywall.st
BridgeBio: New Data Bolsters The Bull Case (NASDAQ:BBIO) - Seeking Alpha
BridgeBio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025 | BBIO Stock News - GuruFocus
BridgeBio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025 - The Manila Times
BridgeBio Management Reveals Latest Genetic Disease Strategy at Goldman Sachs Healthcare Conference 2025 - Stock Titan
BridgeBio Pharma (NASDAQ:BBIO) Rating Lowered to “Sell” at Wall Street Zen - Defense World
Nuveen Asset Management LLC Cuts Holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - Defense World
Possible Bearish Signals With BridgeBio Pharma Insiders Disposing Stock - simplywall.st
BridgeBio Pharma’s SWOT analysis: stock soars on Attruby success, pipeline potential - Investing.com Nigeria
Propionic Acidemia Market Statistics Expected to Experience Major Growth by 2034, According to DelveInsight | Bridge Bio Pharma, HemoShear Therapeutics, Moderna Therapeutics - Barchart.com
Cetera Investment Advisers Takes $1.02 Million Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - Defense World
The Play On BridgeBio Pharma: Great Expectations For Attruby (NASDAQ:BBIO) - Seeking Alpha
BridgeBio’s Acoramidis: A Breakthrough in ATTR-CM Treatment - Insider Monkey
Trading (BBIO) With Integrated Risk Controls - news.stocktradersdaily.com
Acoramidis Reduced Incidence of Atrial Fibrillation Events in Patients with ATTR-CM - marketscreener.com
BridgeBio (BBIO) Shares Positive Phase 3 Study Data | BBIO Stock News - GuruFocus
Acoramidis Reduced Incidence of Atrial Fibrillation Events in Patients with ATTR-CM | BBIO Stock News - GuruFocus
Breakthrough: New ATTR-CM Treatment Cuts Heart Complications by 43%, Shows Fastest Clinical Benefits Ever - Stock Titan
BridgeBio’s acoramidis shows promise in ATTR-CM study By Investing.com - Investing.com Nigeria
BridgeBio Pharma Reports Phase 3 Data Linking TTR Increase to Improved Survival With Acoramidis - marketscreener.com
BridgeBio’s acoramidis shows promise in ATTR-CM study - Investing.com
BridgeBio Pharma Reports Positive Phase 3 Results for Acoramidis, Highlighting Improved Survival Rates in ATTR-CM Patients - Nasdaq
Breakthrough ATTR-CM Study: Higher TTR Levels from Acoramidis Directly Predict 31% Better Survival Rates - Stock Titan
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Wall Street Analysts Believe BridgeBio Pharma (BBIO) Could Rally 63.87%: Here's is How to Trade - MSN
Why BridgeBio Pharma, Inc. (BBIO) Declined on Tuesday - Yahoo Finance
Fibroblast Growth Factors (FGFs) Market reached US$ 303.75 - openPR.com
Bridgebio Pharma Inc (BBIO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.91%
1.17%
자본화:
|
볼륨(24시간):